CClinicalTrials.gg
RecruitingNCT07428629RISE-UCUpdated Aug 28, 2026

Piloting an Insomnia Treatment in Patients With Ulcerative Colitis

An interventional study of CBT-I UC in Insomnia and Ulcerative Colitis, sponsored by Dartmouth-Hitchcock Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Dartmouth-Hitchcock Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if telehealth-based Cognitive Behavioral Therapy for Insomnia (CBT-I) adapted for Ulcerative Colitis (UC) works to treat insomnia in adults with UC. The main questions it aims to answer are:

  • Is telehealth-based CBT-I adapted for UC feasible and acceptable to participants?
  • Does CBT-I for UC impact insomnia severity and sleep continuity?

Participants will:

  • Answer questionnaires online before and after treatment
  • Complete an online daily sleep diary before, during, and after treatment
  • Participate in 5 telehealth treatment visits over 7-8 weeks
  • Participate in 5-10-minute phone calls between treatment visits
02

Conditions studied

  • Insomnia
  • Ulcerative Colitis

Keywords

  • telehealth
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Active UC based on PRUCSI
  • Insomnia Severity Index score > 8 and SOL or WASO > 30 minutes
  • Stability of sleep \& UC meds for > 3 months
  • Access to internet or cell phone service sufficient for telehealth

Exclusion criteria

Exclusion Criteria:

  • PHQ-9 depression score > 15
  • GAD-7 anxiety score > 15
  • Unstable major psychiatric condition (e.g., bipolar disorder, psychotic disorder)
  • Current alcohol or substance abuse
  • Current opioid use for pain control
  • Current systemic corticosteroid use
  • Current pregnancy or nursing
  • Ileostomy or colostomy
  • Diagnosis of seizure disorder
  • Diagnosis of sleep apnea
  • Diagnosis of restless leg syndrome or positive Cambridge-Hopkins RSLq screen
  • Night shift, rotating shift work, or frequent travel outside of time zone
  • Residence in a state where we cannot conduct telehealth visits
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    CBT-I UC Treatment

    All participants entered into the study will receive telehealth CBT-I for UC.

    Behavioral: CBT-I UC

Interventions

  • BehavioralCBT-I UC

    This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.

05

What researchers measure

Primary outcomes

  1. Retention

    Measured based on the percentage of participants who complete the full study.

    Time frame: Baseline, 8 weeks

  2. Recruitment rate

    Recruitment rate will be based on the average number of participants who are enrolled into the trial per month.

    Time frame: From study initiation until we are no longer actively recruiting (approximately 3 months)

  3. Acceptability

    Visit completion will be based the number of visits (out of 5) completed by each participant.

    Time frame: 8 weeks

  4. Treatment acceptability questionnaire score

    The Treatment Acceptability Questionnaire is a 4-item self-report questionnaire designed to assess the overall acceptability of an intervention. Scores range from 1 to 4 and higher scores are indicative of greater acceptability.

    Time frame: 1 week

Secondary outcomes

  1. Change in insomnia symptoms as measured by the Insomnia Severity Index

    The Insomnia Severity Index (ISI) is a self-report questionnaire designed to measure severity of insomnia. The ISI is made up of 7 items on insomnia symptoms and related impairments and total scores range from 0-28. Higher scores are indicative of greater insomnia symptoms.

    Time frame: Baseline, 8 weeks

  2. Change in diary-based sleep onset latency

    A weekly average of self-reported time it takes to fall asleep each night, derived from a self-reported sleep diary

    Time frame: Baseline, 8 weeks

  3. Change in diary-based wake after sleep onset

    A weekly average of self-reported time spent awake in the middle of each night, derived from a self-reported sleep diary

    Time frame: Baseline, 8 weeks

  4. Change in diary-based sleep efficiency

    Change in sleep efficiency (total sleep time / time in bed), derived from a self-reported sleep diary.

    Time frame: Baseline, 8 weeks

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07428629
Lead sponsor
Dartmouth-Hitchcock Medical Center
Responsible party
Jessica.K.Salwen-Deremer (Assistant Professor of Psychiatry, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Feb 24, 2026
Start date
Apr 17, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Aug 28, 2026

Study contacts

Jessica K Salwen-Deremer, PhD
Contact
jessica.k.salwen-deremer@hitchcock.org
(603) 650-5261

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion